An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)

Inclusion Criteria: 1. Patients who signed written informed consent form 2. age between 18-60 years, female or male 3. diagnosed IgA Nephropathy (IgAN) by renal biopsy during 1 months 4. renal biopsy had: 10%\< crescents\<50%; endocapillary hypercellularity; or necrosis ,and interstitial fibrosis\<50%, 5. proteinuria\>1g/24h for two times Exclusion Criteria: 1. secondary IgA Nephropathy (IgAN); 2. eGFR\<30ml/min/1.73m2.( MDRD formula) 3. liver disfunction; 4. uncontrolled hypertension 5. WBC \<3000/mm3 6. Severe viral infection(HBV, HCV, CMV) within 3 months ofor known HIV infection. 7. diabetes or obesity(BMI\>28) ; 8. severe infection or central nervous system symptoms.